首页 | 本学科首页   官方微博 | 高级检索  
     


VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma
Authors:P Preis  W Scheithauer  E Fritz  C Zielinski  I Kuehrer  A Cortelezzi  E Polli  L Baldini  R Pirker  A Kriegisch
Affiliation:2nd Department of Internal Medicine, Vienna, Austria.
Abstract:Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号